Membrane Vesicles as Drug Delivery Systems: Source, Preparation, Modification, Drug Loading, In Vivo Administration and Biodistribution, and Application in Various Diseases
-
Published:2023-07-07
Issue:7
Volume:15
Page:1903
-
ISSN:1999-4923
-
Container-title:Pharmaceutics
-
language:en
-
Short-container-title:Pharmaceutics
Author:
Sun Chenhan1, Qin Ying1, Zhuang Hongda1, Zhang Yuan1, Wu Zhiwen1, Chen Yong1ORCID
Affiliation:
1. Jiangxi Key Laboratory for Microscale Interdisciplinary Study, Institute for Advanced Study, Nanchang University, Nanchang 330031, China
Abstract
Bioinspired (or biologically inspired) drug delivery systems (DDSs) have been intensively studied in the last decades. As bioinspired DDSs, membrane vesicles, including extracellular vesicles (EVs) released from eukaryotic cells, outer membrane vesicles (OMVs) from bacteria, cell-bound membrane vesicles (CBMVs) isolated in situ from cell surfaces, membrane vesicles reorganized after the isolation of the plasma membrane of cells, and others have been rapidly developed and are attracting more and more attention. Most recently, a collection of 25 papers on the advances in membrane vesicle-based drug delivery systems was published in a Special Issue of Pharmaceutics entitled “Advances of membrane vesicles in drug delivery systems”. These papers cover many related topics including the source, preparation, modification, drug loading, and in vivo administration and biodistribution of membrane vesicles (mainly extracellular vesicles or exosomes and bacterial outer membrane vesicles), as well as application of membrane vesicles as DDSs in the treatment of various diseases.
Funder
National Natural Science Foundation of China Natural Science Foundation of Jiangxi Province of China Interdisciplinary Innovation Fund of Nanchang University
Subject
Pharmaceutical Science
Reference34 articles.
1. Wei, B., Li, Y., Ao, M., Shao, W., Wang, K., Rong, T., Zhou, Y., and Chen, Y. (2022). Ganglioside GM3-functionalized reconstituted high-density lipoprotein (GM3-rHDL) as a novel nanocarrier enhances antiatherosclerotic efficacy of statins in apoE−/− C57BL/6 mice. Pharmaceutics, 14. 2. Rong, T., Wei, B., Ao, M., Zhao, H., Li, Y., Zhang, Y., Qin, Y., Zhou, J., Zhou, F., and Chen, Y. (2021). Enhanced anti-atherosclerotic efficacy of pH-responsively releasable ganglioside GM3 delivered by reconstituted high-density lipoprotein. Int. J. Mol. Sci., 22. 3. Identification and characterization of cell-bound membrane vesicles;Tang;BBA-Biomembr.,2017 4. Isolated cell-bound membrane vesicles (CBMVs) as a novel class of drug nanocarriers;Zhang;J. Nanobiotechnol,2020 5. Cell-bound membrane vesicles contain antioxidative proteins and probably have an antioxidative function in cells or a therapeutic potential;Zhou;J. Drug Deliv. Sci. Technol.,2023
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|